In response to a growing trend of pharmaceutical price gouging, several presidential candidates have released plans1 to limit the rising cost of pharmaceuticals, some of which specifically target large pharmaceutical entities that have demonstrated a strategic preference for acquiring smaller drug companies with established therapies, as opposed to developing products internally.
Nguyen HP, Forman HP. A Policy-Driven Perspective on Rising Drug Costs in Dermatology. JAMA Dermatol. 2016;152(6):625-626. doi:10.1001/jamadermatol.2016.0349